Clinical Trials
12 trialsNCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT05012254 2026-05-05
NIVIPI-Brain
Fundación GECP
Phase 2 Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06926790 2025-04-22
GALAXY 3
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06492421 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04300244 2024-02-29
NIPU
Oslo University Hospital
Phase 2 Active not recruiting
NCT05041062 2024-01-03
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
Phase 2 Completed
NCT03406715 2023-03-30
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01820754 2021-02-26
TOP1201 IPI
Duke University
Phase 2 Completed
NCT03256136 2020-11-04
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Massachusetts General Hospital
Phase 2 Completed
NCT00527735 2018-07-18
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
Phase 2 Completed